1Fang Z Y, Sharman J, Prins J B, et al. Determinants of exercise capacity in patients with type 2 diabetes [ J ]. DiabetesCare, 2005, 28: 1643.
2Kantor P F, Lucien A, Kozak R, et al. The antiangina/drug trimetazidine shifts cardiac energymetabolism from fatty acidoxidation to glucose oxidation by inhibiting mitochondrial long -chain 3 -ketoacyl coenzyme a thiolase[J]. Circ Res, 2000, 86 : 580.
3Sentex E, Helies-Tussaint C, Rousseau D, et al. Influence of trimetazidine on the synthesis of complex lipids in the heart and other target organs[J]. Fundarn Clin Pharmacol, 2001, 15 : 255.
4DiNapoli P, Tacacrdi A A, Barsutti A. Zong term cardiop rotective action of trimetazidinl and potential ehect on the imflammatory process in patients with ischaemic dilated cardiomy opatuy[J]. Heart, 2005, 91: 161.
5Allibardl S, Chierehia S L, Margonato V, et al. Effect s of t rim2etazidine on metabolic and functional recovery of postischemic rathearts[J]. Cardiovasc Drugs Ther, 2001, 12: 543.
